These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 12113052)
1. Treatment of refractory and relapsed acute myelogenous leukemia. Stanisic S; Kalaycio M Expert Rev Anticancer Ther; 2002 Jun; 2(3):287-95. PubMed ID: 12113052 [TBL] [Abstract][Full Text] [Related]
2. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481 [TBL] [Abstract][Full Text] [Related]
3. Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly. Piccaluga PP; Martinelli G; Rondoni M; Malagola M; Ronconi S; Visani G; Baccarani M Haematologica; 2003 Dec; 88(12):ECR37. PubMed ID: 14688010 [No Abstract] [Full Text] [Related]
4. Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia. Giles FJ Expert Rev Anticancer Ther; 2002 Dec; 2(6):630-40. PubMed ID: 12503209 [TBL] [Abstract][Full Text] [Related]
5. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. Zittoun RA; Mandelli F; Willemze R; de Witte T; Labar B; Resegotti L; Leoni F; Damasio E; Visani G; Papa G N Engl J Med; 1995 Jan; 332(4):217-23. PubMed ID: 7808487 [TBL] [Abstract][Full Text] [Related]
6. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817 [TBL] [Abstract][Full Text] [Related]
7. Treatment of relapsed or refractory acute promyelocytic leukemia. Tallman MS Best Pract Res Clin Haematol; 2007 Mar; 20(1):57-65. PubMed ID: 17336255 [TBL] [Abstract][Full Text] [Related]
8. Autologous bone marrow transplantation for leukemia. Stuart RK Semin Oncol; 1993 Oct; 20(5 Suppl 6):40-54. PubMed ID: 8211215 [TBL] [Abstract][Full Text] [Related]
9. Treatment of relapsed acute myeloid leukemia with MLL/AF6 fusion after allogeneic hematopoietic stem cell transplantation with gemtuzumab ozogamicin with a long interval followed by donor lymphocyte infusion. Tamai H; Shioi Y; Yamaguchi H; Okabe M; Wakita S; Mizuki T; Nakayama K; Inokuchi K; Tajika K; Dan K Leukemia; 2008 Jun; 22(6):1273-4. PubMed ID: 17989711 [No Abstract] [Full Text] [Related]
10. Successful induction of molecular remission with single-agent anti-CD33 antibody (gemtuzumab ozogamicin) in chemotherapy-refractory relapse of acute myeloid leukaemia post-BMT. Swords R; Hayden PJ; Molloy K; Lawlor M; Browne PV; Murphy PT Eur J Haematol; 2004 Dec; 73(6):450-1. PubMed ID: 15522070 [No Abstract] [Full Text] [Related]
11. Comparison of Autologous and Unrelated Transplants for Cytogenetically Normal Acute Myelogenous Leukemia. Mizutani M; Takami A; Hara M; Mizuno S; Yanada M; Chou T; Uchiyama H; Ohashi K; Miyamoto T; Ozawa Y; Imataki O; Kobayashi N; Uchida N; Kanamori H; Kamimura T; Eto T; Onizuka M; Tanaka J; Atsuta Y; Yano S Biol Blood Marrow Transplant; 2017 Sep; 23(9):1447-1454. PubMed ID: 28533061 [TBL] [Abstract][Full Text] [Related]
12. Antibody-targeted chemotherapy for the treatment of relapsed acute myeloid leukemia. Williams JP; Handler HL Am J Manag Care; 2000 Oct; 6(18 Suppl):S975-85. PubMed ID: 11184568 [TBL] [Abstract][Full Text] [Related]
13. Azacitidine combined with gemtuzumab ozogamicin in patients with relapsed/refractory acute myeloid leukemia. Bayraktar UD; Domingo GC; Schmit J; Pereira D Leuk Lymphoma; 2011 May; 52(5):913-5. PubMed ID: 21417821 [No Abstract] [Full Text] [Related]
14. Gemtuzumab ozogamicin-induced long-term remission in a woman with acute myelomonocytic leukemia and bone marrow relapse following allogeneic transplantation. Sumi M; Ichikawa N; Nasu K; Shimizu I; Ueki T; Ueno M; Kobayashi H Int J Hematol; 2009 Dec; 90(5):643-647. PubMed ID: 19904520 [TBL] [Abstract][Full Text] [Related]
15. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Wong R; Shahjahan M; Wang X; Thall PF; De Lima M; Khouri I; Gajewski J; Alamo J; Couriel D; Andersson BS; Donato M; Hosing C; Komanduri K; Anderlini P; Molldrem J; Ueno NT; Estey E; Ippoliti C; Champlin R; Giralt S Biol Blood Marrow Transplant; 2005 Feb; 11(2):108-14. PubMed ID: 15682071 [TBL] [Abstract][Full Text] [Related]
16. Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant. Owonikoko T; Agha M; Balassanian R; Smith R; Raptis A Nat Clin Pract Oncol; 2007 Aug; 4(8):491-5. PubMed ID: 17657254 [TBL] [Abstract][Full Text] [Related]